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METHODS
Phosphorylation of Akt, mTOR, the downstream effectors eukaryotic initiation factor 4E binding protein 1 (4EBP1) and S6 ribosomal protein (S6) were evaluated in BxPC-3 human pancreatic cancer cells treated with Yttrium-90 ( 90 Y) labeled anti-integrin α6β4 antibody (ITGA6B4) and BEZ235 by western blotting. The cytotoxic effect of BEZ235 was investigated using a colony formation assay. Therapeutic efficacy enhancement by oral BEZ235 administration was assessed using mice bearing BxPC-3 xenograft tumors. Tumor volume measurements and immunohistochemical analyses (cell proliferation marker Ki-67, DNA damage marker p-H2AX and p-4EBP1 staining) of tumors were performed for evaluation of combined treatment with 90 Y-ITGA6B4 plus BEZ235, or each arm alone.
RESULTS
We found that phosphorylation of Akt (p-Akt), 4EBP1 (p-4EBP1) and S6 (p-S6) was inhibited by BEZ235. 
INTRODUCTION
Pancreatic cancer is one of the most difficult malignant diseases to cure [1] . Its treatment options are limited including surgery, adjuvant chemotherapy, and radiation therapy and have not given encouraging outcomes so far. A possible solution might emerge from the use of targeted therapy such as radioimmunotherapy (RIT) [2] . RIT involves a selective internal radiation therapy using cytotoxic radionuclides conjugated to tumor-directed antibodies [3] . We recently reported the results obtained from a preclinical study of RIT using a novel monoclonal anti-integrin α6β4 antibody (ITGA6B4) labeled with beta-emitter Yttrium-90 ( Y-ITGA6B4 showed significant anti-tumor effects, the myelotoxicity caused by an overdose was a major challenge to overcome [4] . To counteract this problem, the feasibility of reducing the radiation dose by combining other therapeutic modalities and retaining the same or better therapeutic effect is important. Thus, combining RIT with other chemotherapeutic candidates is one of the options to reduce the radiation dose to normal organs especially bone marrow.
The phosphatidylinositol-3-kinase (PI3K)/Akt/ mammalian target of rapamycin (mTOR) pathway is a critical intracellular signaling pathway involved in regulating cell metabolism and survival, cell cycle progression, proliferation, adhesion, and migration, particularly during cancer progression, metastasis, and radioresistance [5] [6] [7] [8] [9] [10] . Moreover, this pathway is frequently aberrant and activated in cancer cells. Several downstream targets including the serine/ threonine kinase Akt that activates mTOR are activated by PI3K. Furthermore, activation of this pathway is known to decrease sensitivity to chemotherapeutics as well as to irradiation (IR) [11, 12] , resulting in a limited treatment outcome. The PI3K/Akt and mTOR signaling pathways are also frequently dysregulated in pancreatic ductal adenocarcinoma (PDAC) [13] .
Meanwhile, BEZ235 (also known as NVP-BEZ235, Dactolisib) is a potent dual pan-class I PI3K and mTOR inhibitor that suppresses PI3K and mTOR kinase activity and has been tested in preclinical studies for many cancers to demonstrate remarkable anticancer effects [14] . This orally administrable inhibitor is the first PI3K/mTOR dual inhibitor to undergo clinical trials [15, 16] , and already shown promising cytostatic results in breast cancer treatment [17] . Cao et al [18] reported that acute oral dosing with BEZ235 strongly suppressed the phosphorylation of protein kinase B (PKB)/Akt in primary human pancreatic cancers grown as orthotopic xenografts. They also showed the inhibition of downstream Thr37/46 eukaryotic initiation factor 4E binding protein 1 (4EBP1) and Ser235/236 S6 ribosomal protein (S6), consistent with the effects of BEZ235 as a dual PI3K/ mTOR inhibitor [18] . Matsushima et al [19] reported that the phosphorylation of Akt (p-Akt), 4EBP1 (p-4EBP1), and S6 (p-S6) was inhibited in BEZ235-treated MBT-2 murine bladder cancer cells. Similarly, Kuger et al [20] reported that inhibiting the PI3K/Akt/mTOR pathway with BEZ235 caused dephosphorylation of the transcription and translation regulators 4EBP1 and S6. Although several studies have demonstrated that BEZ235 could be a potential radiosensitizer to external radiation therapy [21] [22] [23] [24] [25] [26] [27] [28] [29] , there are currently no reports evaluating BEZ235 as a suitable drug to improve the therapeutic effect of RIT. The present study aimed to investigate whether the combination of RIT with molecular targeting BEZ235 therapy could enhance the therapeutic efficacy.
MATERIALS AND METHODS

Cell culture and drug preparation
Human pancreatic cancer cell line BxPC-3 was purchased from American Type Culture Collection (Manassas, VA, United States) and cultured in Roswell Park Memorial Institute (RPMI) 1640 medium (Sigma-Aldrich, St. Louis, MO, United States) supplemented with 10% fetal bovine serum (FBS, Nichirei Biosciences, Tokyo, Japan), 100 U/mL penicillin G sodium, and 100 mg/mL streptomycin sulfate (Invitrogen, Carlsbad, CA, United States) at 37 ℃ in a humidified atmosphere containing 5% CO2.
NVP-BEZ235 was purchased from Selleck Chemicals (Houston, TX, United States), dissolved in dimethyl sulfoxide (Sigma-Aldrich) and the 2.5 mmol/L stock was stored at -20 ℃. For in vivo treatment, it was mixed with the vehicle NMP/polyethylene glycol 300 (10/90, v/v).
Antibody radiolabeling
Human anti-α6β4 monoclonal antibody (IgG1) was labeled with beta-emitter 90 Y, as previously reported [30] . Briefly, the antibody solution and a chelating agent, 
Western blot analysis
Western blotting was performed to analyze the proteins of interest from cultured cells. Cancer cells were cultured and treated with medium containing 0.1 μmol/L BEZ235 or DMSO (vehicle) for 1 h. The medium was then discarded and cells were exposed to medium containing 90 Y-ITGA6B4 (indicated doses 185 and 370 kBq/mL) in the presence and absence of BEZ235 treatment. At 18 h after incubation, whole-cell lysates were prepared using radioimmunoprecipitation assay buffer (Wako Pure Chemical Industries, Osaka, Japan) with protease inhibitor cocktail. Total protein concentration was measured using the NanoDrop One Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, United States). Protein samples (45 μg) were separated on a 4%-20% polyacrylamide gel (ATTO Corporation, Tokyo, Japan) and transferred to an Immobilon-P membrane (Millipore, Billerica, MA, United States). The following antibodies: antihuman phospho-Akt (Ser473) (D9E) monoclonal antibody, anti-human phospho-4EBP1 (Thr37/46) (236B4) monoclonal antibody, anti-human phosphomTOR (Ser2448) (D9C2) monoclonal antibody, antihuman phospho-S6 Ribosomal protein (Ser235/236)
Mouse pancreatic tumor xenograft model
All animal experiments were performed in accordance with the animal experimentation protocol approved by the Animal Care and Use Committee of National Institute of Radiological Sciences. Nude mice (7-wkold female BALB/cA Jcl-nu/nu mice) were obtained commercially from CLEA, Shizuoka, Japan. They were housed in a restricted access room and acclimatized to standard laboratory conditions (23 ℃, 12 h/12 h light/dark, 50% humidity, free access to food and water). Subcutaneous tumors were generated by injecting a suspension of 5 × 10 6 BxPC-3 cells in 100
µL RPMI medium mixed with BD Matrigel matrix (BD Biosciences, Bedford, MA, United States) into the right thigh of nude mice.
In vivo tumor treatment study
When the subcutaneous tumors in mice reached approximately 10 mm at the longest diameter, the xenograft tumor-bearing mice were randomly assigned to 4 groups (n = 10 for each group) for the treatment study. Experimental treatment was performed according to the shown scheme ( Figure 1 ). Group a received daily oral administration of BEZ235 35 mg/kg, 5 d/wk for a 6-wk schedule with a single administration of These were used as primary antibodies. Horseradish peroxidase (HRP)-linked anti-rabbit IgG antibody purchased from GE Healthcare (Little Chalfont, United Kingdom) was used as the secondary antibody. Immunoreactive bands were visualized using the Enhanced Chemiluminescence Plus western blotting detection system (GE Healthcare). Y-ITGA6B4 at 1 h following BEZ235 administration because within this time frame, BEZ235 achieves effective intra-tumoral concentrations [15] . To observe the tumor response, tumor volumes of mice (n = 6 for each group) were measured twice a week throughout the experiment using calipers, and were approximated using the equation: volume (mm 
Colony formation assay
Immunohistochemical analysis
On Day 1 and Day 3 after 90 Y-ITGA6B4 administration, 2 mice of each group (n = 2) were euthanized by cervical dislocation under anaesthesia (Isoflurane). Tumor tissue specimens were extirpated, fixed in 4% paraformaldehyde, and embedded in paraffin. Tumor specimens obtained from untreated mice were used as control. Paraffin-embedded tissue sections were cut (5 μm), rehydrated, and subjected to antigen retrieval. Ki-67 staining of sections was performed using an antihuman Ki-67 polyclonal antibody (Dako Denmark, Glostrup, Denmark), as previously described [31] .
Phospho-Histone H2AX (p-H2AX) and Phospho-4EBP1 (p-4EBP1) staining were also detected using anti-human p-H2AX (Ser139) (20E3) monoclonal antibody and anti-human p-4EBP1 (Thr37/46) (236B4) monoclonal antibody (Cell Signaling technology), respectively. To detect the apoptotic tumor cells, terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining was performed with an ApopTag Peroxidase In situ Apoptosis Detection Kit (Millipore Corporation, Temecula, CA, United states). Each slide was observed using the Olympus BX43 microscope system (Olympus, Tokyo, Japan). For quantitative and statistical analysis, we counted the number of Ki-67-positive cells observed in three random fields of view at 200× magnification in 2 different tumors sections from each group (n = 6). similarly, p-H2AX-positive cells were also counted.
Statistical analysis
All results were expressed as mean ± SD. Figure 4A ). At 27 d after starting the treatment, the combination treatment showed 30.9% or 53.9% further reduction of the tumor volume ratio compared to that attained with RIT alone or BEZ235 alone, respectively. Neither significant average body weight loss ( Figure 4B ) nor differences in general conditions of mice were observed between the groups throughout the experiment.
RESULTS
BEZ235
Immunohistochemical evaluation of the therapeutic effects of combined 90 Y-ITGA6B4 plus BEZ235 treatment or each arm alone
Proportions of cell positive for the cell proliferation marker protein [32] Ki-67 were decreased in tumor sections of mice treated with the combination 90 Y-ITGA6B4 plus BEZ235, or each arm alone, when compared with those of the control group. It is wellknown that phosphorylation of the histone variant H2AX (p-H2AX) is a highly specific and sensitive molecular marker to monitor both DNA double-strand break (DSB) initiation and resolution, especially during radiation treatment [33] . P-H2AX-positive cells were increased in tumor sections of mice receiving the combined treatment or 90 Y-ITGA6B4 treatment alone, when compared with those in the control group. The quantitative results and statistical analysis were summarized in Table 1 . Immunohistochemical staining with the p-4EBP1 antibody depicted decreased expression of p-4EBP1 in the combined treatment or each arm alone, when compared with that in the control ( Figure 5 ). On the other hand, TUNEL-positive cells were rare and there was no clear difference in the TUNEL staining patterns among all the groups (Data not shown).
DISCUSSION
several previous in vitro and in vivo studies have revealed that BEZ235 could be a potential radiosensitizer in the treatment of various cancers such as fibrosarcoma as well as hypopharyngeal carcinoma [21] , prostate carcinoma [22, 23] , non-small cell lung cancer (NSCLC) [24] , glioblastoma [25] , colorectal cancer (CRC) [26] , and breast cancer [34] . Chen et al [26] reported that inactivation of the PI3K/Akt pathway by BEZ235 could enhance radiosensitivity by hindering the PI3K/Akt/mTOR pathway and DNA repair mechanisms. To prevent the radiation induced activation of PI3K/Akt/mTOR Values are expressed as mean ± SD, n = 6. b P < 0.01 vs Vehicle, signaling, they treated the colorectal cancer cells with BEZ235 one hour before the radiation and found that BEZ235 synergistically inhibited cell viability. Their findings are in accordance with those of Kuger et al [27] demonstrating that radiosensitivity of glioblastoma cells was enhanced by BEZ235 exposure one hour before irradiation. Some recent studies described that BEZ235 could potently inhibit major DNA damage response kinases, attenuate the repair of irradiationinduced DNA damage, and confer striking tumor radiosensitization in glioblastoma [25, 29] .
In contrast to external beam radiation therapy, one of the convincing benefits of RIT is its capacity to strike the primary tumor as well as the systemically metastasizing and residual lesions. However, systemic administration of large amounts of radiolabeled antibodies may cause bone marrow suppression. Small but adequate quantities of radiolabeled antibody that may bind to targets and produce efficient cytotoxic effects are therefore desirable, and new strategies are consequently needed to improve the effectiveness of RIT. We speculated that the combination of RIT and BEZ235 may help reduce the dose of RIT and generate a greater therapeutic response than each arm used alone, with less frequent treatment-related toxicity and increased radiosensitivity. The radiophysical properties of [4] . as the treatment protocol, we used a single administration of Y-ITGA6B4 once-weekly (3.7 MBq × 2) in our previous study [4] . We found significantly reduced tumor growth rates in both groups compared with those in the untreated control. However, one mouse from the group receiving the double administrations showed pale skin and few petechiae during the study, and died on day 22 following the first dose. We considered myelotoxicity due to an overdose as the cause of death because analysis of hematological parameters at day 27 after starting the RIT indicated decreased RBC, WBC, and platelet counts in mice treated with double administrations, whereas only a decreased RBC count was observed in mice receiving a single administration. Based on these previous results [4] , we chose a single administration dose of 90 Y-ITGA6B4 (2.8 MBq) for RIT in this study design. Moreover, we decided to include daily oral administration of BEZ235 35 mg/kg, 5 d/wk over a 6-wk schedule. To the best of our knowledge, this is the first report about the combined therapeutic effects of RIT and BEZ235 in a preclinical pancreatic cancer model.
In the present study, inhibition of the PI3K/Akt/ mTOR pathway with BEZ235 was proven by western blotting in BxPC-3 tumor cells upon observing the downregulation of p-Akt, as well as the downstream targets, p-4EBP1 and p-S6. The reduction of p-Akt, p-4EBP1 and p-S6 suggested that a plausible mechanism of the cytotoxic effect of BEZ235 derived from inhibition of the PI3K/Akt/mTOR pathway. The 4EBP1 protein integrates its function at the level of translation regulation [35] . Recently, it has been shown that some kinases phosphorylate 4EBP1 dependent or independent of mTOR, indicating that mTOR may not be the only kinase that phosphorylates 4EBP1 [36] , and that 4EBP1 is regarded as a point of convergence of various signaling pathways [35] . Phosphorylation of S6 ribosomal protein correlates with an increase in the translation of mRNA transcripts encoding proteins involved in cell cycle progression as well as ribosomal proteins and elongation factors necessary for translation [37] . Upregulation of mRNA translation is effectively involved in sustained cell growth and proliferation [37] . The opposite effect was observed with BEZ235 treatment.
The cytotoxic effect of BEZ235 on BxPC-3 cells was evaluated using the colony formation assay. with appropriate timings will be required and will be interesting to address in next study. Concerning toxicity, we can judge that there was no enhancement of toxicity during the combined treatment because body weight loss, obvious abnormal changes in general conditions and death were not observed in the mice receiving treatment ( Figure 4B ). Previously, Fokas et al [28] has demonstrated that BEZ235 itself causes DNA damage even in nonirradiated cells, as evidenced by moderately increased phosphorylation of the histone variant H2AX, and the enhanced persistence of p-H2AX foci after irradiation, thus attributing radiosensitivity to head and neck and bladder cancer cell lines. In our immunohistochemical analyses, significantly increased DNA damage marker p-H2AX-positive cells were noted in the tumor sections of mice that received Y-ITGA6B4 administration (data not shown). This result is in line with the results of our previous RIT study in which TUNEL assay was conducted at 2 d post-administration [4] . Chen et al [26] have reported that irradiation upregulates the Akt/mTOR signaling pathway including the activation of Akt and mTOR, which were attenuated by BEZ235 pretreatment. Likewise, RIT may also upregulate Akt/mTOR signaling pathway to some extent after administration, but it seems that this activated Akt/mTOR signaling pathway is attenuated by BEZ235 pretreatment. The mechanisms underlying the treatment with BEZ235 in combination with RIT for pancreatic cancer still need to be clarified with a more detailed study covering evidences at multiple timespoints during treatment with various dose regimens of both drugs. In the current study, we obtained an insight in to the presumptive mechanism of a combination treatment with PI3K/mTOR inhibitors and RIT as well as its therapeutic effects.
In conclusion, our findings imply that it is possible to improve the therapeutic efficacy by combining 90 Y-ITGA6B4-mediated radioimmunotherapy with the dual PI3K and mTOR inhibitor, BEZ235, and this combination is a promising treatment option for future pancreatic cancer therapy, though many hurdles remain to be overcome to reach clinical use.
COMMENTS
Background
Pancreatic cancer is one of the most difficult malignant diseases to cure. Its treatment options are limited and have not given encouraging outcomes so far. A possible solution might emerge from the use of radioimmunotherapy (RIT) and other molecular targeting chemotherapeutic candidates. The phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is frequently dysregulated and activated in human cancers including pancreatic cancer. Several studies have revealed that BEZ235 (NVP-BEZ235) can inhibit the PI3K and mTOR kinase activity, could be a potential radiosensitizer, and has been used in preclinical studies in many cancers with excellent results of anticancer effects.
Research frontiers
The authors have studied the radioimmunotherapeutic effect and toxicity of Yttrium-90 labeled anti-integrin α6β4 antibody ( 90 Y-ITGA6B4) in a mouse pancreatic cancer model. In the previous study, 90 Y-ITGA6B4 showed antitumor effects but myelotoxicity caused by an overdose was a major handicap. To overcome this obstacle, combining RIT with other chemotherapeutic candidates is one of the options for reducing the radiation dose and retaining the therapeutic effect.
Innovations and breakthroughs
To the best of our knowledge, there was no report about the therapeutic effects of combined 90 Y-ITGA6B4-RIT and BEZ235 in cancer treatment. Thus, The authors examined this effect for the first time in a pre-clinical pancreatic cancer xenograft model.
Applications
These in vitro and in vivo studies and results suggest that it is possible to improve the therapeutic efficacy by combing 90 Y-ITGA6B4-RIT and BEZ235 and this combination can be a potential encouraging treatment option for future pancreatic cancer therapy.
Terminology
The 90 Y-ITGA6B4-RIT is a specific treatment option for cancer by cytotoxic radionuclide (beta-emitter Yttrium-90) conjugated to anti-integrin α6β4 monoclonocal antibody (ITGA6B4). The PI3K/Akt/mTOR pathway is a Figure 5 Ki-67, p-H2AX, p-4EBP1 immunostaining of tumor sections. A: On Day 1 and; B: On Day 3 after administration of 90Y-ITGA6B4 alone or combined with BEZ235, intratumoral proliferation was determined by immunostaining for Ki-67 nuclear antigen. A marked reduction in Ki-67-positive cell numbers was observed in samples from mice treated with 90Y-ITGA6B4 + BEZ235 as well as with 90Y-ITGA6B4 alone and BEZ235 alone, compared with those in the untreated control sample. Meanwhile, increased p-H2AX-positive cell numbers were observed in samples from mice that received 90Y-ITGA6B4 treatment alone or the combined treatment than those in the control. Immunohistochemical analysis for p-4EBP1 showed that phosphorylation of 4EBP1 was decreased in the treatment groups compared with the control group. Tumor section images were acquired at 200× magnification and representative images are shown (scale bar, 50 μm). The quantitative and statistical analysis were summarized in Table 1 .
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